Stock Track | Novo Nordisk Plummets 5.02% Intraday on Disappointing 2026 Outlook Amid Pricing Pressure and Competition

Stock Track02-04

Novo-Nordisk A/S (NVO) shares plummeted 5.02% during intraday trading on Wednesday, extending a sharp decline from the previous session.

The sell-off was triggered by the Danish pharmaceutical giant's weaker-than-expected financial guidance for 2026. The company warned that adjusted sales and operating profit could decline between 5% and 13% this year, a steeper drop than analysts had anticipated. Management cited "unprecedented pricing pressure" in the United States for its blockbuster weight-loss drugs Wegovy and Ozempic as a primary headwind.

This pricing pressure stems from a recent agreement with the U.S. government to lower drug costs for Americans, part of the "Most Favored Nation" policy initiatives. Additionally, Novo Nordisk faces intensifying competition from rival Eli Lilly in the lucrative obesity drug market, patent expirations for its key drug ingredient semaglutide in certain international markets, and the persistent challenge of compounded, lower-cost copycat versions of its medications circulating in the U.S. The disappointing outlook overshadowed a strong initial launch for its new Wegovy pill and better-than-expected fourth-quarter 2025 results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100264418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100264418","market":"hk","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plummets 5.02% Intraday on Disappointing 2026 Outlook Amid Pricing Pressure and Competition","media":"Stock Track","content":"<p>Novo-Nordisk A/S (NVO) shares plummeted 5.02% during intraday trading on Wednesday, extending a sharp decline from the previous session.</p><p>The sell-off was triggered by the Danish pharmaceutical giant's weaker-than-expected financial guidance for 2026. The company warned that adjusted sales and operating profit could decline between 5% and 13% this year, a steeper drop than analysts had anticipated. Management cited \"unprecedented pricing pressure\" in the United States for its blockbuster weight-loss drugs Wegovy and Ozempic as a primary headwind.</p><p>This pricing pressure stems from a recent agreement with the U.S. government to lower drug costs for Americans, part of the \"Most Favored Nation\" policy initiatives. Additionally, Novo Nordisk faces intensifying competition from rival Eli Lilly in the lucrative obesity drug market, patent expirations for its key drug ingredient semaglutide in certain international markets, and the persistent challenge of compounded, lower-cost copycat versions of its medications circulating in the U.S. The disappointing outlook overshadowed a strong initial launch for its new Wegovy pill and better-than-expected fourth-quarter 2025 results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plummets 5.02% Intraday on Disappointing 2026 Outlook Amid Pricing Pressure and Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plummets 5.02% Intraday on Disappointing 2026 Outlook Amid Pricing Pressure and Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo-Nordisk A/S (NVO) shares plummeted 5.02% during intraday trading on Wednesday, extending a sharp decline from the previous session.</p><p>The sell-off was triggered by the Danish pharmaceutical giant's weaker-than-expected financial guidance for 2026. The company warned that adjusted sales and operating profit could decline between 5% and 13% this year, a steeper drop than analysts had anticipated. Management cited \"unprecedented pricing pressure\" in the United States for its blockbuster weight-loss drugs Wegovy and Ozempic as a primary headwind.</p><p>This pricing pressure stems from a recent agreement with the U.S. government to lower drug costs for Americans, part of the \"Most Favored Nation\" policy initiatives. Additionally, Novo Nordisk faces intensifying competition from rival Eli Lilly in the lucrative obesity drug market, patent expirations for its key drug ingredient semaglutide in certain international markets, and the persistent challenge of compounded, lower-cost copycat versions of its medications circulating in the U.S. The disappointing outlook overshadowed a strong initial launch for its new Wegovy pill and better-than-expected fourth-quarter 2025 results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1100264418","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100264418","pubTimestamp":1770217032,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo-Nordisk A/S (NVO) shares plummeted 5.02% during intraday trading on Wednesday, extending a sharp decline from the previous session.The sell-off was triggered by the Danish pharmaceutical giant's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股赛道|定价压力和竞争下2026年前景令人失望诺和诺德盘中暴跌5.02%","themeId":"d8deb89374e43b6f3f7a293c95d7622d","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo-Nordisk A/S (NVO) shares plummeted 5.02% during intraday trading on Wednesday, extending a sharp decline from the previous session.The sell-off was triggered by the Danish pharmaceutical giant's weaker-than-expected financial guidance for 2026. The company warned that adjusted sales and operating profit could decline between 5% and 13% this year, a steeper drop than analysts had anticipated. Management cited \"unprecedented pricing pressure\" in the United States for its blockbuster weight-loss drugs Wegovy and Ozempic as a primary headwind.This pricing pressure stems from a recent agreement with the U.S. government to lower drug costs for Americans, part of the \"Most Favored Nation\" policy initiatives. Additionally, Novo Nordisk faces intensifying competition from rival Eli Lilly in the lucrative obesity drug market, patent expirations for its key drug ingredient semaglutide in certain international markets, and the persistent challenge of compounded, lower-cost copycat versions of its medications circulating in the U.S. The disappointing outlook overshadowed a strong initial launch for its new Wegovy pill and better-than-expected fourth-quarter 2025 results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100264418","isCrawlerRequest":true}